Genentech’s Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell…
Avastin Fully Approved For Most Aggressive Form Of Brain Cancer
The U.S. Food and Drug Administration (FDA) has granted full approval for Genentech’s Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA’s accelerated approval program. “Glioblastoma is the most common and aggressive form of…